Strong eradication rates with first-
line treatment

NONINFERIORITY ENDPOINT IN PATIENTS WITHOUT AMOXICILLIN- OR CLARITHROMYCIN-RESISTANT STRAINS OF H. PYLORI (mITT)

Image of bar graph showing noninferiority endpoint in patients without amoxicillin- or clarithromycin-restrain strains of H. pylori. 85% eradication rate with VOQUEZNA® Triple Pak® (vonoprazan, amoxicillin, clarithromycin). And 79% for VOQUEZNA® Dual Pak® (vonoprazan, amoxicillin) and Lansoprazole triple therapy

Powerful H. pylori
eradication rates

Eradication rates in the per-protocol population (PP) were consistent
with the mITT population²

NONINFERIORITY ENDPOINT IN PATIENTS WITHOUT AMOXICILLIN-
OR CLARITHROMYCIN-RESISTANT STRAINS OF H. PYLORI (PP)

Image of a bar graph showing the noninferiority endpoint in parties without amoxicillin- or clarithromycin-resistant strains of H. pylori. Eradication rates were 90% for VOQUEZNA® Triple Pak® (vonoprazan, amoxicillin, clarithromycin), 81% for VOQUEZNA® Dual Pak® (vonoprazan, amoxicillin), and 82% for Lansoprazole triple therapy

Eradication rate for
VOQUEZNA Triple Pak
in the PP population
was 90%

Explore more data with VOQUEZNA-based regimens

SEE SAFETY PROFILE RESULTS IN
ALL-PATIENTS COHORT